Adverse reactions reported in 2% of patients and at a rate greater than placebo are shown in Table 4
THE LANDMARK TRIAL PENN STATE, 6 MONTHS, PEER-REVIEWED: A 6-month randomized, double-blind, placebo-controlled human trial of 54 adults at Penn State University (Richie et al., European Journal of Nutrition, 2015) found that oral Setria L-Glutathione at 250 mg/day produced significant increases in whole-blood glutathione levels at 1, 3, and 6 months versus baseline establishing for the first time that oral glutathione is bioavailable in humans
That is different from claiming that a microdose has special brain-protective effects
Trial Design and Population: SELECT enrolled 17,604 adults 45 years with overweight/obesity (BMI 27) and established CVD (MI, stroke, PAD), but without diabetes
Women may start using the transdermal contraceptive system immediately after a first-trimester abortion
Many injured individuals are now taking legal action through products liability litigation